Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease
Clinical Hematology International · 21.10.2024 · 6 (4)
DOI: 10.46989/001c.124926 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Hematology International, online erschienen am 21.10.2024. Verfasst von Rahul Shah und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine The University of Texas MD Anderson Cancer Center. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic graft-versus-host disease (cGVHD) represents a common long-term complication after allogeneic hematopoietic stem cell transplantation (HSCT). It imposes a significant morbidity burden and is the leading cause of non-relapse mortality among long-term HSCT survivors. cGVHD can manifest in nearly any organ, severely affecting the quality of life of a transplant survivor. While the mainstay of treatment has remained systemic immunosuppression with glucocorticoids, progress has been made within the last few years with approvals of three oral agents to treat steroid-refractory cGVHD: ibrutinib, ruxolitinib, and belumosudil. Iatrogenesis contributes a significant portion of the morbidity experienced by patients with cGVHD, primarily from glucocorticoids. This review highlights the myriad impacts of cGVHD, including and beyond the traditional organ systems captured by the National Institutes of Health Consensus Criteria, including iatrogenic complications of long-term immunosuppression. It presents the implications of cGVHD and its treatment on cardiovascular and metabolic health, bone density, endocrine function, sexual health, and ocular and pulmonary disease and outlines a framework around the comprehensive multidisciplinary approach for its evaluation and management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cancer Medicine The University of Texas MD Anderson Cancer Center.
- Department of Medicine Vanderbilt University Medical Center.
- Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center.
- Division of Hematology/Oncology, Department of Pediatrics Vanderbilt University Medical Center.
ORCID-Profile: Rahul Shah
Zitieren
APA
Shah, R., Murphy, D., Logue, M., Jerkins, J., Jallouk, A., Adetola, K., Oluwole, O., Jayani, R., Biltibo, E., Kim, T. K., Sengsayadeth, S., Chinratanalab, W., Kitko, C., Savani, B., & Dholaria, B. (2024). Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease. Clinical Hematology International, 6(4). https://doi.org/10.46989/001c.124926
Vancouver
Shah R, Murphy D, Logue M, Jerkins J, Jallouk A, Adetola K, et al. Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease. Clinical Hematology International. 2024;6(4). doi:10.46989/001c.124926
BibTeX
@article{Shah2024,
author = {Shah, Rahul and Murphy, Danielle and Logue, Melissa and Jerkins, James and Jallouk, Andrew and Adetola, Kassim and Oluwole, Olalekan and Jayani, Reena and Biltibo, Eden and Kim, Tae K and Sengsayadeth, Salyka and Chinratanalab, Wichai and Kitko, Carrie and Savani, Bipin and Dholaria, Bhagirathbhai},
title = {Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease},
journal = {Clinical Hematology International},
year = {2024},
volume = {6},
number = {4},
doi = {10.46989/001c.124926}
}
EUVIMED